Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down prior to trading on Monday . The stock had previously closed at $43.55, but opened at $40.72. Nanobiotix shares last traded at $39.7950, with a volume of 63,402 shares.

Analyst Ratings Changes

Several brokerages have commented on NBTX. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. UBS Group boosted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Leerink Partners upped their price target on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.33.

Nanobiotix Trading Up 4.7%

The business has a 50-day moving average price of $38.80 and a 200 day moving average price of $35.73.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors and hedge funds have recently modified their holdings of NBTX. Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth about $390,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix during the fourth quarter valued at $220,000. Finally, Royal Bank of Canada increased its position in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.